Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable

Six months after its launch, the Trump administration's flagship drug pricing website, TrumpRx, has failed to deliver the sweeping discount supermarket it promised. An NPR analysis reveals that only 92 brand-name prescription drugs are currently covered under the voluntary agreements brokered with 17 pharmaceutical companies—fewer than 12% of the 800-plus brand-name medicines those firms market in the United States. The shortfall is particularly acute in therapeutic areas that drive the highest costs: treatments for inflammatory conditions, HIV, and cancer are largely absent from the portal. The website, launched in February 2026, was the public-facing result of a May 2025 executive order that commanded American drug prices to be aligned with—or fall below—those paid in other wealthy nations. In the summer of 2025, the administration sent letters to 17 major drugmakers, demanding direct-to-consumer sales at lower prices and granting 60 days to comply voluntarily before threatening the use of tariffs and other unspecified tools. The negotiations that followed were described as closed-door, with the specter of tariffs hanging over them, but the output, as of mid-July 2026, is a boutique selection rather than the promised supermarket. This limited outcome carries significant implications. It signals that Big Pharma, while willing to make highly visible, limited concessions, is avoiding any broad restructuring of its U.S. pricing model. Companies like Eli Lilly and Novo Nordisk had already begun direct-to-consumer sales for certain drugs before the executive order, so their participation may reflect existing commercial strategies rather than a response to government pressure. The absence of medicines for HIV, cancer, and inflammatory diseases—segments where insurers and patients bear enormous costs—suggests that drugmakers are protecting their most profitable franchises. From a policy perspective, TrumpRx's underperformance weakens the administration's narrative that aggressive negotiation and tariff threats can rapidly reshape drug pricing without legislative change. It also leaves vulnerable populations, including those dependent on generic drugs (which account for 90% of U.S. prescriptions) and independent pharmacists caught in the crossfire of tariff disputes, without meaningful relief. The boutique nature of the site may even backfire by highlighting the gap between political rhetoric and market reality. Looking ahead, the administration faces a credibility challenge. To expand coverage, it will likely need to escalate pressure, potentially using tariffs or regulatory action. However, such moves risk supply disruptions and legal pushback, potentially eroding the industry goodwill that any voluntary framework requires. For patients and payers, the TrumpRx experience underscores the durability of pharmaceutical pricing power and the difficulty of achieving significant change through administrative fiat alone. The coming months may see renewed calls for legislative price negotiation, particularly if public disappointment grows. The 92 deals represent a start, but until the numbers meaningfully dent the 800-strong brand-name portfolio, TrumpRx will remain a symbol of promised transformation that fell short.